Joe Fletcher | VP, IR |
David Ricks | Chairman, CEO & President |
Anat Ashkenazi | EVP & CFO |
Daniel Skovronsky | EVP, Chief Scientific & Medical Officer and President |
Anne White | EVP & President, Lilly Neuroscience Lilly Research Laboratories |
Jake Van Naarden | EVP, CEO, Loxo Oncology & President, Lilly Oncology |
Patrik Jonsson | EVP, Chief Customer Officer, President, Lilly USA & Lilly Immunology |
Michael Mason | EVP & President of Lilly Diabetes |
Louise Chen | Cantor Fitzgerald & Co. |
Geoff Meacham | Bank of America Merrill Lynch |
Timothy Anderson | Wolfe Research |
Robyn Karnauskas | Truist Securities |
Stephen Scala | TD Cowen |
Umer Raffat | Evercore ISI |
Carter Gould | Barclays Bank |
Kerry Holford | Berenberg |
Terence Flynn | Morgan Stanley |
Colin Bristow | UBS |
Christopher Schott | JPMorgan Chase & Co. |
David Risinger | Leerink Partners |
Chris Shibutani | Goldman Sachs Group |
Trung Huynh | Crédit Suisse |
Mohit Bansal | Wells Fargo Securities |
Andrew Baum | Citigroup |
Evan Seigerman | BMO Capital Markets |
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2023 Earnings Call. [Operator Instructions].
I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.
Good morning.